Note 3 Supplemental Financial Information

Interest Expense, Net

years ended December 31 (in millions)	2014			2013			2012

Interest expense	$	429		$	299		$	104
Interest and dividend income		(38	)		(21	)		(20	)

Interest expense, net	$	391		$	278		$	84

Interest expense, net in 2014 included $141 million of financing related fees incurred in connection with the terminated proposed combination with Shire.

Other Income, Net

Other income, net, includes income from the resolution of certain contractual agreements, fair value adjustments to contingent consideration, and impairments of equity securities. Other income, net in 2014 primarily consisted of income of $34 million from the resolution of a contractual agreement.

Accounts Payable and Accrued Liabilities

as of December 31 (in millions)	2014		2013

Sales rebates	$	1,384	$	1,401
Accounts payable		881		933
Due to Abbott Laboratories		536		876
Dividends payable		791		643
Salaries, wages and commissions		623		621
Royalty license arrangements		821		443
Other		1,918		1,531

Accounts payable and accrued liabilities	$	6,954	$	6,448

Long-Term Liabilities

as of December 31 (in millions)	2014		2013

Deferred income taxes	$	630	$	570
Pension and other post-employment benefits		2,220		1,628
Other		990		1,337

Long-term liabilities	$	3,840	$	3,535